COVID-19 Rules and Solutions

Updated April 7, 2020

Hospitals across the country are reaching out to us with requests for clinical surveillance support related to COVID-19. We’re responding by creating new rules, alerts, and reports on an almost daily basis.

To ensure you are aware of these resources available to you, we’ve assembled the two below lists:

  • List 1 is a compilation of the rules, alerts, and reports that are currently available.
  • List 2 is a compilation of the rules, alerts, and reports that are available to your hospital by request. These have been implemented at other hospitals based on their unique needs and challenges.

We update these lists regularly by posting the newest rules at the top.

List 1: Rules, alerts, and reports currently available

Infection prevention:

  • Syndromic screening for COVID-like illnesses (monitoring of vitals, imaging, and notes to identify possible patients who have not tested positive, yet need to be isolated)
  • Alerts for all who have testing ordered, as well as patients who have tested positive and negative
  • Alerts to identify patients who are at high risk and alerts to identify disease clusters
  • Rules and alerts to identify patients missed through all other means of screening and identification, i.e. leveraging ICD-10 billing codes specific to COVID-19
  • Reports to gauge the COVID-19 burden on the hospital (including data on admissions, testing, ICU utilization, ventilator utilization, and medication utilization)
  • Tools to work up employee exposures, furlough needs, testing, and disease acquisition
  • Tools that streamline reporting to public health partners. NHSN recently introduced a COVID-19 Patient Impact and Hospital Capacity Module within its Patient Safety Component. We are developing an on-demand report that includes the requested information, such as daily counts of confirmed and suspected COVID-19 patients and use and availability of beds and ventilators.

Pharmacy surveillance:

  • *NEW* Customer webinars:
    • Pharmacy Module: COVID-19 Rules and Report
      Thursday, April 9, 2020
      2:00PM- 2:20 PM CTThis webcast presentation will review potential rules around COVID-19 and a new Ad Hoc report built to identify COVID-19 patients. Register here.
    • Pharmacy Module: Managing Drug Shortages
      Tuesday, April 14th, 2020
      10:30AM-11:00 AM CTThis webcast will present all the tools within VigiLanz to effectively to manage a drug shortage. Register here.
  • Alerts when specific medications are ordered to help limit their use (and ensure the proactive identification of patients on medications that may be in short supply due to COVID-19)
  • Alerts when patients on medications that are in short supply could be switched to alternative therapies
  • Real-time reports that identify patients with active orders for particular drugs
  • Immediate notification to staff related to drug shortages and the process for handling certain drugs by using the Client Communication Tool on the VigiLanz home/landing page

In addition, we’ve created a new COVID-19 Testing Results report that can help all of your hospital’s relevant healthcare providers better care for COVID-19 patients. This report compiles all patients with a COVID-19 order, positive/negative lab result, or positive microbiology report. In addition, it includes patient demographics, clinical parameters like temperature, SpO2, FiO2, medications, and discharge disposition. As with all of our reports, it can be exported to Excel after it’s generated.

List 2: COVID-19 rules, alerts, and reports available by request

Please note – these can be enabled based on your individual needs, and on the data feeds that are available at your site. Please submit an IssueTrak ticket for customized support.

Infection prevention:

  • Alerts when COVID-19 patients are readmitted
  • Alerts when patients have been discharged but test positive
  • Alerts when COVID-19 patients are discharged
  • Line list reports
  • Vented patient reports
  • COVID-19 patients that need ventilators reports
  • Expired COVID-19 patients reports
  • Total positives over time reports
  • Identify inpatients who are being prescribed inhalers but who are not under isolation

Pharmacy surveillance:

  • COVID-19 treatment ordered: remdesivir, hydroxychloroquine, chloroquine, darunavir, lopinavir, tocilizumab
  • Inhalers ordered for patients not on isolation
  • Nebulized meds ordered for COVID-19-positive patients
  • Prolonged QTc with hydroxychloroquine +/- azithromycin
  • Missing baseline QTc with hydroxychloroquine
  • Reports for a daily review of meds to minimize the number of admins/day (minimize PPE consumption)
  • Support daily medication reviews by pharmacists to minimize the number of required clinician contacts with suspected or known positive COVID-19 patients

VigiLanz Ranked No. 1 by KLAS Research Across Three Categories for the Third Year

Clinical surveillance company recognized again as a KLAS leader in antimicrobial stewardship, infection control and monitoring, and pharmacy surveillance


MINNEAPOLIS – Feb. 4, 2020 – VigiLanz, a clinical surveillance company, today announced that it has earned 2020 Category Leader designations from KLAS Research for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance. This is the second year VigiLanz has been recognized by KLAS as a Category Leader across all three areas, and the third year to earn that distinction in Infection Control and Monitoring and Pharmacy Surveillance, prior to the Antimicrobial Stewardship category being added in 2019.

Three VigiLanz products were recognized in the “2020 Best in KLAS: Software and Services” report, released on January 31:

VigiLanz Dynamic Infection Control Monitor

Earning a score of 92.7, the Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s EHR. Its automatic exception-based alert system puts all patient records under continuous surveillance to alert decision makers in real time of potential infections, MDROs, isolation candidates, organism clusters, conditions of concern, and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

“I really like the ability to adapt the rules in Dynamic Infection Control Monitor. Interpreting rules is much easier now than it was with our last system. My infection control team is not super tech savvy, and my people have other tasks and jobs to worry about. The system makes doing their jobs easy for them.”

  • Manager, August 2019,

VigiLanz Dynamic PharmacoVigilance

Earning a score of 92.8, Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, it automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“The versatility of the VigiLanz system is its strength. We have been able to leverage rule abilities on many fronts. The product is excellent. It does a great job with tasking and the workflow of identifying patients. The product is very robust.”

  • Analyst/Coordinator, August 2019, com

VigiLanz Antimicrobial Stewardship

Earning a score of 93.3, the Antimicrobial Stewardship product monitors antimicrobial therapy to ensure appropriate use, including unnecessary antibiotic therapy, de-escalation opportunities, positive rapid diagnostic test results, drug-bug mismatches, and opportunities for antibiotic “time-outs.” The Antimicrobial Stewardship dashboard shows usage and resistance trends across the organization, is Meaningful Use 3 certified, and provides direct reporting to the Centers for Disease Control’s National Healthcare Safety Network.

“VigiLanz doesn’t provide software where we have to fill in the blanks. The software has a framework that allows us to create our own world. The software is limitless. In this ever-changing world, the VigiLanz product is what we need for healthcare.”

  • Director, November 2019,

“Our customers’ trust in our clinical surveillance products is the highest level of affirmation we can achieve,” said VigiLanz Chairman and CEO David Goldsteen, MD. “We strive to exceed our customers’ expectations year over year. We are proud to be recognized as a Category Leader for three years running. To the customers who asserted their confidence in us and our products – thank you. We will continue to set the bar higher and support you in building healthier hospitals.”

The KLAS Category Leader designation is awarded to vendors that lead select market segments in which at least two products meet a minimum number of KLAS Konfidence reviews. Rankings are based on customer surveys of North American healthcare leaders, administrators, clinicians, and others who interact with the solutions.




About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit


About VigiLanz

Founded in 2001, VigiLanz ( is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

My Favorite VigiLanz Rule: Pharmacists and IPs Share Their Top Picks

At VigiLanz, data rules! And as a VigiLanz customer, you can create more actionable data by tapping into our extensive rules library or creating new rules based on your unique needs. Our clinical experts are always standing by to help, whether you need help adjusting an existing rule or creating something new.

We’ve gathered some inspiration from real VigiLanz customers on their favorite and unique VigiLanz rules that have a significant impact on patient care.


Biofire Alert

Jeremy Frens, PharmD, BCPS-AQID, Antibiotic Stewardship Coordinator at Cone Health

“My favorite rule is the positive Biofire alert. We have customized the alert so that our antimicrobial stewardship team and ID physicians get email or text alerts based on the organism detected. Our hospital has a policy that an ID physician sees patients with Staph aureus, Candida, or enterococcal bacteremia. With the text or email alerts going directly to them, they can respond quickly, often the same day as the alert. We feel that this process helps to streamline antibiotics more quickly!”

High Risk C. difficile

Erica Lawrence, MSN, RN, Infection Preventionist at Virginia Mason Medical Center

“My favorite one is the high risk C. difficile rule. This rule helps to alert us proactively of patients at risk for C. difficile, but not necessarily diagnosed or symptomatic with C. diff. This allows for the AMS group to review prescribed medications and make recommendations to the providers if de-escalation of antibiotics or gastric acid suppressors is appropriate. Another intervention is adding signs and symptoms of C. difficile to the discharge instructions to ensure patients are educated about when to follow up with their provider if signs and symptoms of C. difficile begin after discharge.”

Critical Medication Discontinued

Jill Bennett, PharmD, APh, BCPS, Clinical Pharmacy Coordinator at Antelope Valley Hospital

“Some of my favorite rules are the ones that alert us to medications that have been discontinued when that might be detrimental to a patient outcome. For example: Levetiracetam DC’d and no active anticonvulsant order, or in patients with prolonged LOS when routine medications may fall off the profile from an ASO: Inpatient Day #30 – Check Med Profile. The real-time culture info is also nice.”

Patient Discharge SNF

Chrissie Wiebe, Infection Preventionist at Maury Regional Medical Center

“I would have to say my favorite rule we have is the “Pt Discharge SNF (CMP-QI Grant Locations)”. I like this rule because we are able to track patients who are going to certain nursing homes at discharge using keywords in their documentation. This rule is helpful because we have a grant that is allowing us to work with certain local nursing homes to help prevent readmission. This rule allows us to know which patients are going to these locations so we can get a better idea as to where our patients are going and how we can best serve the SNF’s in order to prevent a possible readmission for something they can take care of at their facility.”

Highly Infectious Disease Email Alerts

Jordan Ehni, CIC, MPH, Systems Integration Infection Preventionist at Mount Sinai Health System

“I think my favorite rule/function are the email alerts that we can set up for when a patient with a highly infectious disease comes into the hospital. We don’t have time to constantly check VigiLanz throughout the workday, so it is good to know we have this ‘back up’ alert if we go a few hours between checking our Isolation Bucket.”

Highly Infectious Disease Email Alerts

Sarah Lowtharp, MSN, RN, CIC, Assistant Director of Infection Prevention at St. Bernards Medical Center

“My favorite rules are centered on alerting us of highly infectious patients immediately. I get an email alert from a rule trigger in VigiLanz on possible meningitis, possible TB, CROs, and possible Candida auris (the Candida isolates we are required to send to dept. of health for auris testing). I usually receive my email/VigiLanz alert before our own lab notifies us of these scenarios.”


Real-Time Blood Culture Contamination Results

Frank Vanskike, MPH, CIC, Infection Preventionist at Phoenix Children’s

“We worked with our VigiLanz team to build a rule around blood culture contamination results in our ED. These reports alerted us in real-time as opposed to the previous method where we were provided the contamination rate at the end of the month. We were able to build a report off of the rule and disseminate to the ED and stakeholders on a weekly basis. This intervention helped us track when and where contamination on blood draws were occurring so real-time education and feedback could be provided. Furthermore, this helped the ED because the report enabled us to communicate to the ED patients that had contaminated specimens that were not true infections and did not need to return to the ED to seek treatment. This saved a return visit to the hospital for families, avoided potential readmissions, prevented unnecessary antibiotic use, and eliminated unnecessary financial costs.”


Metabolic Support Consult for ICU & Ventilator Patients

Adrienne Carey, PharmD, BCPS, Clinical Pharmacist / Data Mining Program Manager at Freeman

“We created a group of rules to alert our Metabolic Support Team to the fact that a patient in our ICU is on a ventilator and may need a metabolic support consult for enteral or parenteral nutrition management. A metabolic support consult can sometimes get overlooked in these patients since at the time of admission they do not have an immediate need for nutritional support and no order for such is entered by a physician, but these patients still need to be monitored closely as after a period of time on sedation, they will need nutritional support. Our Metabolic Support Team is alerted to about 30 patients per month with these rules.”

Real-time Antimicrobial Stewardship Improves Care at Intermountain Healthcare

Laurie Blankenship, PharmD, Pharmacy Director at Park City Hospital of Intermountain Healthcare, discusses the benefits of working with VigiLanz on a daily basis.

“I can remember five years ago, when we didn’t have VigiLanz or any kind of software for antimicrobial stewardship, and we didn’t have nearly as many good catches and we didn’t make nearly as many interventions,” says Blankenship.

Watch this short video to learn more about how Blankenship and her team are using VigiLanz to improve patient care.



I am the pharmacy director at Park City Hospital, which is one of the 23 hospitals at Intermountain Healthcare. It’s a community hospital, so it’s a little bit smaller. We only have 37 beds. Because of the size, I’m more of a working director. So I do a lot of clinical work. I do work with VigiLanz on a daily basis. I’m the co-chair of the Antimicrobial Stewardship Committee that we have at Park City Hospital.

I can remember five years ago when we didn’t have VigiLanz or any kind of software for antimicrobial stewardship and we didn’t have nearly as many good catches and we didn’t make nearly as many interventions.

VigiLanz helps keep us up to date on any cultures or results. So it’s the real time feature—so important because it gives us all that feedback right when it’s currently happening. Instead of looking through the medical chart and trying to find those blood cultures or the urine cultures, VigiLanz gives us that real time data. So it allows us to make more appropriate antibiotic choices, shortened duration of therapy, identify if there’s a bug drug mismatch and even identify discharged patients, which is a really big thing that we use it for. If the patient went home and their culture grew something that we need to change therapy, it’s a great tool for identifying those patients that are already out of our system.

My favorite part of working with VigiLanz is that we have all the information in one portal for antimicrobial stewardship. It includes our emergency room, it includes our ICU, it includes our med-surg, and all of it, again, is in real time. We have all that at our fingertips and an easily accessible tool to help us make the best decisions and to help us tailor and recommend, make awesome recommendations to physicians and to improve patient care. That’s the most important thing.

The Sharp Experience: Measuring the ROI of Clinical Surveillance | ASHP 2019

A technology’s return on investment can be measured in many ways. One of the key ROI measures at Sharp HealthCare—a San Diego-based health system made up of four acute-care hospitals, three specialty hospitals, and various medical groups and other facilities—is how well the technology supports its “Pillars of Excellence.”

Each day, Sharp HealthCare strives to achieve excellence in its seven Pillars of Excellence: Quality, Safety, Service, People, Finance, Growth and Community. And, the health system is finding that VigiLanz’s clinical surveillance platform is helping it achieve that goal.

Specifically, VigiLanz has created innovation and spurred improvements in safety, quality, finance, and people, says Mike Kruse, PharmD, MBA, BCPS, Manager of Pharmacy Clinical Services at Sharp HealthCare. At ASHP Midyear 2019, Kruse shared more about how VigiLanz is impacting the health system.


Adventist Health Uses VigiLanz to Curb Infections

Customer Profile

Adventist Health and Rideout, a nonprofit community-based health system in Marysville, California, provides services across the full spectrum of care, including general medical/surgery, intensive care, and cancer care. Comprised of an acute-care hospital and numerous medical centers, it is known for high quality and high patient satisfaction.


Hospitals across the country are experiencing high rates of hospital-acquired infections (HAIs). In fact, more than 800 health systems incurred reimbursement penalties from Medicare in 2019 because of too many HAIs, and one out of every 25 patients develops an infection while in hospitals, according to The Leapfrog Group.

Over the past few years, Adventist Health and Rideout has made reducing HAIs, particularly C. diff, a top priority. As a key part of this initiative, it has focused on reducing overprescribing of antibiotics, which is a common problem in hospitals, and which contributes to the rise in infections.

“We were struggling with overprescribing, with rates that exceeded the national average for similar hospitals of similar sizes,” explained Bryce Whitesides, PharmD, Pharmacy Operations Manager at Adventist Health and Rideout. “We were determined to improve our performance. We knew if we could improve, we’d see fewer infections.”


Before embarking on its initiative to curb HAIs, Adventist Health and Rideout was already using basic functions of VigiLanz’s platform to monitor patient care and fill in their EMR’s quality and reporting gaps. Still, Brock Taylor, PharmD, Clinical Manager at Adventist Health and Rideout, suspected the technology platform was underutilized.

“I spoke to our VigiLanz clinical support member who explained how we could use the technology to create more targeted and customized rules that would trigger alerts related to different types of data, such as prescribing data or lab data,” said Taylor. “The pharmacy team and infection prevention team then identified rules that we thought would be most helpful in monitoring and curbing infections.”

Now, pharmacists and physicians receive real-time alerts and if a red flag arises related to antibiotic prescribingfor example, if there is a mismatch between the medication ordered and the patient’s conditionpharmacists reach out to prescribing physicians to discuss the medication and determine if alternative approaches should be considered.

Closer Collaborations

As part of the Adventist Health and Rideout approach, pharmacists contact physicians for discussions when they receive alerts related to antibiotic prescribing. Initially, some physicians resisted this approach, so an infectious disease specialist (rather than pharmacists) began to initiate the contact with ordering physicians. “Over time, as physicians realized they could trust the alerts, they were willing to comply with the pharmacists’ recommendations—which helped drive down the rate of inappropriate antibiotic prescriptions,” said Whitesides.

To further ensure appropriate antibiotic use, Adventist Health and Rideout’s infectious disease specialist and pharmacy clinical manager receive alerts if physicians prescribe an antibiotic that has restricted indications, such as ceftazidime/avibactam. Again, when this occurs, they work with prescribing physicians to ensure the prescription is appropriate.

“We developed these rules strategically so that pharmacists could provide clinical interventions more quickly if necessary,” explained Whitesides. “We’re making sure that we don’t contribute to the rise in infections in hospitals or in the community after patients are discharged.”

Adventist Health and Rideout also uses VigiLanz to help pharmacists and infection prevention team members determine if an infected patient acquired their infection in the hospital or in the community prior to or after the hospital visit. That’s because VigiLanz sends alerts as soon as lab data indicates a patient has an infection, such as C. diff. Since pharmacists and infection prevention team members are notified so quickly, it’s easier for them to determine the origin of the infection.

As the hospital has become better at identifying the origin, pharmacists and infectious disease team members have found that many of the infections they would have traditionally reported as HAIs actually originated in the community, said Whitesides. As a result, the hospital has improved its quality metrics related to HAIs.

“Before it was difficult to know if a C. diff infection was hospital or community acquired,” he said. “Now, we can show how our antibiotic optimization is working, and demonstrate that we’re helping to lower the community-acquired C. diff rates. We’re not sending patients home with unnecessary or prolonged antibiotic prescriptions.”


The continued focus on appropriate use of antibiotics, and on the de-escalation of antibiotic use when appropriate, has improved patient care at Adventist Health and Rideout. It has also led to significant cost savings.

C. diff. infections have fallen from several monthly to approximately one every other month, and use of Zosyn and other broad-spectrum antibiotics has declined significantly, said Whitesides.

The the hospital is now meeting national standards for antibiotic utilization, and annual antibiotic usage expenditures have fallen $500,000 per year.

“Our finances have steadily improved over the past five years. While a number of initiatives have contributed to that, VigiLanz has played a large role.”
– Bryce Whitesides, PharmD, Pharmacy Operations Manager

Recently, Adventist Health West System, a large integrated health system which owns Adventist Health and Rideout, decided to replicate Adventist Health and Rideout’s more optimized use of VigiLanz throughout all of its hospitals. Now, there are more than 20 medical centers on the West Coast and Hawaii using VigiLanz to support their efforts to curb HAIs and optimize antibiotic use.

“VigiLanz is a very powerful tool that we’ve used to make very significant interventions, not only in our patients lives but the hospital at large,” said Whitesides. “The impact continues to grow.”


To learn more about how VigiLanz helps hospitals improve their patient safety and clinical surveillance, visit today.

VigiLanz Supports Opioid Stewardship Initiatives at Houston Methodist

Hospitals Fight Back Against the Opioid Epidemic With VigiLanz

The opioid epidemic is one of the most challenging safety problems hospitals face, and VigiLanz is helping address it. The technology alerts physicians and pharmacists if a safety issue arises, such as if a patient is prescribed multiple opioids or has been taking an opioid longer than recommended.

Houston Methodist hospital is using VigiLanz to identify duplicate opioid orders and high use areas. In a recent study, the hospital found that opioid alerts triggered by VigiLanz led to the discontinuation of one or more opioids 53% of the time.


VigiLanz Supports Program that Reduces Rate of Acute-Kidney Injury

VigiLanz Supports Innovative New Approach at Cincinnati Children’s Hospital

Nephrotoxic medications are critical for many patients. Unfortunately, they can also sometimes lead to acute-kidney injury in pediatric patients. To address this problem, Cincinnati Children’s Hospital Medical Center created a complex algorithm to identify patients at risk. The program has led to a 40 percent reduction in AKIs.

VigiLanz supports the program by monitoring patient datawith a complex set of exposure criteria and alerting providers in near real-time if a patient has been exposed to nephrotoxins. It also lets providers know if injury occurs.


Integrating Clinical Alerts into Clinician Workflows: Houston Methodist’s Approach

Data can help physicians and pharmacists make smarter patient care decisions, but the way in which physicians receive that data plays a huge role in whether the information drives higher-value care.

Physicians benefit most from data that is:

  • Current;
  • Easily integrated into their workflows; and
  • Targeted to their specific needs at that moment in patient care.

Many health systems are struggling to meet these three objectives. In fact, turning data into actionable information is the most pressing health IT challenge healthcare organizations face, according to a recent survey of 100 healthcare executives by Managed Healthcare Executive.

At HIMSS 2019, Nicholas Desai, MD, system chief medical information officer at Houston Methodist, shared how his organization is addressing this challenge.

To view his full presentation, click here.

To download the PDF case study, click here.

Houston Methodist—which is made up of seven hospitals, eight emergency care centers, and a large network of more than 6,700 affiliated physicians and 675 employed primary care and specialty physicians—recently embarked on a 90-day pilot to test how integrating clinical alerts into its EMR workflow could help physicians and pharmacists make more cost-effective, higher quality care decisions.

About 130 clinicians and 38 pharmacists were involved in the pilot, said Desai, during his presentation at the VigiLanz booth on Wednesday, February 13.

The alerts were pulled from a variety of sources, including Houston Methodist’s own data and data from its partners, such as VigiLanz. The alerts were integrated into the EMR workflow via IllumiCare’s Smart Ribbon.

“The ribbon is an executable file that sits right on top of our [EMR]. It aggregates data and everything right from our [EMR], but the best part is it pulls it all together in one place,” said Desai. “I can call it up when I want it, I can force it to be passive or active.”

Two Tips for Effective Alert Integrations

  • When integrating alerts into the EMR, consider passive and active alerts that you want to make front and center. For example, if there are five drugs your organization is watching and monitoring closely, consider how you can use alerts to highlight those as top of mind for clinicians.
  • Bring various stakeholders to the table to help determine what type of alerts and data should be integrated. For example, if your organization’s PDMP task force is involved, it might reveal that integrating PDMP-related reports is key.

Pilot Results

The results of the pilot are impressive. The organization was able to shift the cost curve within the 90-day mark about $107,000, said Desai.

“Overall, we believe that in 2019, for this hospital, we have an opportunity of 4.5 percent reduction in our costs, which will lead to between $1.7 million and $2.8 million, just for one hospital,” he said. “As an organization, it’s upwards of what appears to be closer to in the ballpark of $18 [million], $19 [million], $20 million dollars.”

Desai said the VigiLanz alerts in the Smart Ribbon are also extremely helpful to pharmacists, because they can see alerts directly in the EMR without needing to go into the VigiLanz app to view them.

“The reality here is we’re giving [clinicians] tools and working with partners like VigiLanz and Illumicare to really bring together the efficiency tools that our providers need,” said Desai. “That’s what matters.”

To learn how health systems are using clinical surveillance to support high-value care, read: “Clinical Surveillance: The Next Step in Value-Based Care.”

Perhaps most importantly, clinicians responded very favorably to the integrated alerts. “Seventy-two percent of doctors, at the end of our pilot said, ‘This is not just valuable, finally you’re giving me a tool that is meaningful,’” said Desai. “In every one of those conversations, cost was important, but not the only reason why they liked the tool. What they liked about it was that this allowed them to see things in a more holistic view in one place.”

This post has been updated from a post previously published on February 28, 2019.

NINJA Program, Supported by VigiLanz, Helps Prevent Pediatric AKI

The following is an excerpt from Pharmacy Practice News. For more information about the collaboration between VigiLanz and Cincinnati Children’s to reduce AKI, please read our press release and learn more about the solution that is functional and customizable for any hospital, regardless of EMR platform.

Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, a new solution enables real-time identification and monitoring of pediatric patients at risk for acute kidney injury (AKI) from exposure to nephrotoxic drugs.

So far, the program appears to be putting a significant dent in the problem—a greater than 40% reduction in AKI, which the authors contend has reached epidemic proportions in the nation’s hospitals.

Nephrotoxic medication exposure is one of the most common causes of AKI in children. “We know that children need nephrotoxins. These are lifesaving medications,” said Stuart L. Goldstein, MD, the director of the Center for Acute Care Nephrology at Cincinnati Children’s Hospital Medical Center and primary developer of NINJA. “But children should only get the nephrotoxic medications they need for the duration they need them.